Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics

Michael D Ezekowitz1

  • 1Drexel University College of Medicine, 245 North 15th Street - MS 470, Room 6608 NCB, Philadelphia, PA 19102, USA. michael.d.ezekowitz@drexel.edu.

Insights

New anticoagulants are being developed to prevent stroke in patients with atrial fibrillation, offering alternatives to warfarin. These novel drugs aim to improve treatment adherence and outcomes for this growing patient population.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation and heart failure are prevalent, often coexisting conditions.
  • Warfarin is effective for stroke prevention in atrial fibrillation but challenging to manage.
  • Suboptimal translation of clinical trial data into practice necessitates warfarin alternatives.

Purpose of the Study:

  • To review the development of novel anticoagulants as alternatives to warfarin.
  • To assess the clinical progress and potential of direct thrombin inhibitors.

Main Methods:

  • Review of clinical trial data for novel anticoagulants.
  • Evaluation of efficacy, safety, and tolerability profiles.

Main Results:

  • Ximelagatran shows anticoagulant efficacy and bleeding safety but has liver function concerns.
  • Dabigatran is in earlier development with unproven clinical value.
  • Warfarin's complexity limits its widespread optimal use.

Conclusions:

  • Novel anticoagulants are likely to become available for stroke prevention in atrial fibrillation.
  • These alternatives may increase the utilization of anticoagulation therapy.
  • Further research is needed to resolve safety concerns, such as ximelagatran's liver effects.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...